Hu5F9 G4

Drug Profile

Hu5F9 G4

Alternative Names: 5F9; Hu5F9-G4

Latest Information Update: 21 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stanford University
  • Developer Forty Seven; Merck KGaA; Stanford University
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors; SIRPA protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes; Ovarian cancer
  • No development reported Lymphoma

Most Recent Events

  • 13 Aug 2018 Additional efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma, Diffuse large B cell lymphoma, and Follicular lymphoma (Combination therapy, Second-line therapy or greater) released by Forty Seven
  • 31 Jul 2018 Forty Seven sub-licenses patent pertaining to 5F9 from Synthon Biopharmaceuticals
  • 31 Jul 2018 Forty Seven enters into settlement agreement with Synthon Biopharmaceuticals related to patent pertaining to 5F9
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top